<DOC>
	<DOCNO>NCT00518336</DOCNO>
	<brief_summary>Infection human papillomavirus ( HPV ) clearly establish central cause cervical cancer . This Phase IIb study design evaluate long-term efficacy , safety immunogenicity 580299 HPV vaccine ( CervarixTM ) Brazilian cohort woman vaccinate phase IIb , blind , primary study 580299/001 ( NCT00689741 ) participate follow-up study 580299/007 ( NCT00120848 ) . Only subject participate primary &amp; follow-up study enrol long-term follow-up study . Subjects age 15-25 year time entry primary study . The Protocol Posting update order comply FDA Amendment Act , Sep 2007 .</brief_summary>
	<brief_title>Follow-up Study Evaluate Long-term Efficacy HPV Vaccine ( 580299 ) Healthy Young Adult Women Brazil</brief_title>
	<detailed_description>In extension study , woman vaccinate primary study , participate follow-up study , follow visit every 6 month .</detailed_description>
	<criteria>Subjects investigator believe comply requirement protocol enrol study . Subjects participate study 580299007 . Written inform consent obtain subject prior enrollment . Use plan use investigational nonregistered product study vaccine . Decoding subject 's 580299001 treatment allocation either subject investigator . Administration plan administration HPV vaccine , vaccine administer study 580299001 .</criteria>
	<gender>Female</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>25 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>